QQ客服 官方微博 反馈留言

浏览/检索结果: 共18条，第1-10条 帮助 限定条件 发表日期：2021    专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Novel selective kappa agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 11 作者:  Wei, Yuan-yuan;  Ma, Yan;  Yao, Song-yu;  Kong, Ling-hui;  Liu, Xiao 收藏  |  浏览/下载：41/0  |  提交时间：2021/11/04 kappa-opioid receptor agonist  4,5-expoxymorphinan  antinociception  conditioned place aversion  sedation  U50,488H  morphine  Nor-BNI  beta-FNA   Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 13 作者:  Huang, He-ming;  Fan, Shi-jie;  Zhou, Xiao-ru;  Liu, Yan-jun;  Li, Xiao 收藏  |  浏览/下载：58/0  |  提交时间：2021/11/04 nonalcoholic steatohepatitis  inflammation  histone deacetylase inhibitor  givinostat  epigenetics   Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9 作者:  Zhou, Yu-bo;  Zhang, Yang-ming;  Huang, Hong-hui;  Shen, Li-jing;  Han, Xiao-feng 收藏  |  浏览/下载：97/0  |  提交时间：2021/11/04 multiple myeloma  HDAC inhibitor  bisthianostat  pharmacodynamics  pharmacokinetics  phase 1a clinical trial  antitumor drug   Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9 作者:  Liu, Lu;  Li, Wei;  Yang, Le;  Guo, Zi-tao;  Xue, Hao 收藏  |  浏览/下载：80/0  |  提交时间：2021/08/17 almonertinib  itraconazole  rifampicin  drug metabolism  drug interaction  CYP3A  P-gp  pharmacokinetics   SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target 期刊论文 CELL RESEARCH, 2021, 页码: 14 作者:  Xia, Bingqing;  Shen, Xurui;  He, Yang;  Pan, Xiaoyan;  Liu, Feng-Liang 收藏  |  浏览/下载：81/0  |  提交时间：2021/08/17 Histone deacetylase inhibitor givinostat alleviates liver fibrosis by regulating hepatic stellate cell activation 期刊论文 MOLECULAR MEDICINE REPORTS, 2021, 卷号: 23, 期号: 5, 页码: 12 作者:  Huang, He-Ming;  Zhou, Xiao-Ru;  Liu, Yan-Jun;  Fan, Shi-Jie;  Liao, Li-Ping 收藏  |  浏览/下载：46/0  |  提交时间：2021/05/24 liver fibrosis  hepatic stellate cell  histone deacetylase inhibitor  epigenetics  givinostat   Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 18 作者:  Lan, Xiao-fang;  Olaleye, Olajide E.;  Lu, Jun-lan;  Yang, Wei;  Du, Fei-fei 收藏  |  浏览/下载：77/0  |  提交时间：2021/06/11 LianhuaQingwen  glycyrrhetic acid  24-hydroxyglycyrrhetic acid  Gancao-induced pseudoaldosteronism  licorice-induced pseudoaldosteronism  11β  -hydroxysteroid dehydrogenase 2  COVID-19  colonic microbiota   Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun 收藏  |  浏览/下载：72/0  |  提交时间：2021/06/11 metabolism  mass balance  distribution  covalent binding  furmonertinib   Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun 收藏  |  浏览/下载：75/0  |  提交时间：2021/06/11 metabolism  mass balance  distribution  covalent binding  furmonertinib   Natural product 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose is a reversible inhibitor of glyceraldehyde 3-phosphate dehydrogenase 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 13 作者:  Li, Wen;  Liao, Li-ping;  Song, Ning;  Liu, Yan-jun;  Ding, Yi-luan 收藏  |  浏览/下载：83/0  |  提交时间：2021/06/11 glyceraldehyde 3-phosphate dehydrogenase  1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose  hydrogen deuterium exchange mass spectrometry  reversible inhibitor  glycolysis